Rasuvo

    Drug - Rasuvo™ (methorexate for subcutaneous injection) [Medac Pharma Inc.]

    April 2015

    Therapeutic area - Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; psoriasis

    Approval criteria

    Approval will only be granted for diagnoses of rheumatoid arthritis; polyarticular juvenile idiopathic arthritis (pJIA); severe, disabling psoriasis.

    Rheumatoid Arthritis, pJIA approval criteria:

    • Patient must have a diagnosis of rheumatoid arthritis or pJIA AND
    • Patient cannot swallow a tablet whole AND
    • Patient is not taking any other tablet whole by mouth OR
    • Prescriber provides a compelling reason why patient cannot take generically available methotrexate by mouth or injection

    Psoriasis approval criteria:

    • Patient must have a diagnosis of psoriasis AND
    • Patient has tried and failed topical therapy AND
    • Patient cannot swallow a tablet whole AND
    • Patient is not taking any other tablet whole by mouth OR
    • Prescriber provides a compelling reason why patient cannot take generically available methotrexate by mouth or injection

    Quantity limits

    Strength Quantity limit per 28 days
    7.5 mg/0.15 ml 0.6 ml
    10 mg/0.2 ml 0.8 ml
    12.5 mg/0.25 ml 1 ml
    15 mg/0.3 ml 1.2 ml
    17.5 mg/0.35 ml 1.4 ml
    20 mg/0.4 ml 1.6 ml
    22.5 mg/0.45 ml 1.8 ml
    25 mg/0.5 ml 2 ml
    27.5 mg/0.55 ml 2.2 ml
    30 mg/0.6 ml 2.4 ml

    Background information

    Rasuvo™ will only be authorized for approved FDA indications.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top